NIR Legacy of Innovation
First introduced in 1996, Medinol’s revolutionary NIR stent changed the face of cardiovascular intervention. NIR, the first stent to provide simultaneously flexibility and robust scaffolding, revolutionized interventional cardiology by allowing for treatment of longer lesions in more complex anatomies. This enabled clinicians to vastly expand the patient base suitable for stenting, and firmly positioned stenting as the favored treatment over more risky, complex, and expensive surgical intervention.
First Case of the NIR Stent by Dr. Antonio Colombo:
2 stents in 50mm long lesion and 3 stents in 90mm long lesion
Baseline Final Result Baseline Final Result
Legacy of Innovation
In-line with Medinol’s commitment to proven clinical excellence, NIR stents are some of the most clinically-studied Bare Metal Stents ever produced. Since 1995, NIR and its successors have been examined in over 25 clinical studies involving more than 5000 patients.
Since the introduction of the NIR stent, Medinol’s in-house research, development and manufacturing have continuously raised the bar for quality, performance and deliverability of stent systems. With over two million NIR stents delivered to date, our sixth generation coronary stent, the EluNIR™, proudly continues the NIR legacy of innovation.
NIR The first coronary stent to excel in both flexibility and scaffolding
NIR Elite Improved deliverability and conformability
NIRflex New design for exceptional balance between conformability and scaffolding
PioNIR CoCr alloy offering thinner struts and improved crossing profile
NIRxcell Flexx2 technology for unmatched flexibility, pushability and ease-of-delivery
EluNIR The first elastomeric Drug Eluting Stent